Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new safety and ...

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...

Eilersen has announced it is releasing a new series of digital load cells in a hygienic (aseptic) design. The new product is targeted at food and pharmaceutical industry customers and is used for ...

Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...

(MENAFN- Investor Brand Network) Beam Therapeutics (NASDAQ: BEAM) , a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON ...